X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DIVIS LABORATORIES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DIVIS LABORATORIES NOVARTIS/
DIVIS LABORATORIES
 
P/E (TTM) x 391.6 31.4 1,248.1% View Chart
P/BV x 19.3 5.4 354.8% View Chart
Dividend Yield % 1.5 0.9 164.2%  

Financials

 NOVARTIS   DIVIS LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-16
DIVIS LABORATORIES
Mar-17
NOVARTIS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9821,222 80.4%   
Low Rs556784 70.9%   
Sales per share (Unadj.) Rs252.9153.1 165.2%  
Earnings per share (Unadj.) Rs62.139.9 155.6%  
Cash flow per share (Unadj.) Rs63.344.6 141.9%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.31.0 130.4%  
Book value per share (Unadj.) Rs363.6201.8 180.2%  
Shares outstanding (eoy) m31.96265.47 12.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.06.6 46.4%   
Avg P/E ratio x12.425.1 49.3%  
P/CF ratio (eoy) x12.222.5 54.0%  
Price / Book Value ratio x2.15.0 42.6%  
Dividend payout %16.125.0 64.3%   
Avg Mkt Cap Rs m24,580266,266 9.2%   
No. of employees `0000.89.7 7.7%   
Total wages/salary Rs m1,8014,687 38.4%   
Avg. sales/employee Rs Th10,748.94,175.0 257.5%   
Avg. wages/employee Rs Th2,395.2481.5 497.4%   
Avg. net profit/employee Rs Th2,641.11,089.3 242.5%   
INCOME DATA
Net Sales Rs m8,08340,643 19.9%  
Other income Rs m829749 110.7%   
Total revenues Rs m8,91341,392 21.5%   
Gross profit Rs m23414,460 1.6%  
Depreciation Rs m371,233 3.0%   
Interest Rs m223 8.0%   
Profit before tax Rs m1,02513,953 7.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7523,349 22.5%   
Profit after tax Rs m1,98610,604 18.7%  
Gross profit margin %2.935.6 8.1%  
Effective tax rate %73.424.0 305.6%   
Net profit margin %24.626.1 94.2%  
BALANCE SHEET DATA
Current assets Rs m12,67840,105 31.6%   
Current liabilities Rs m2,4336,595 36.9%   
Net working cap to sales %126.782.5 153.7%  
Current ratio x5.26.1 85.7%  
Inventory Days Days33119 27.6%  
Debtors Days Days2281 27.9%  
Net fixed assets Rs m6919,995 0.3%   
Share capital Rs m160531 30.1%   
"Free" reserves Rs m11,46053,043 21.6%   
Net worth Rs m11,62153,574 21.7%   
Long term debt Rs m00-   
Total assets Rs m14,40061,585 23.4%  
Interest coverage x570.5618.4 92.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.7 85.1%   
Return on assets %13.817.3 80.0%  
Return on equity %17.119.8 86.3%  
Return on capital %23.626.1 90.4%  
Exports to sales %0.70-   
Imports to sales %18.625.2 73.6%   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,50310,259 14.6%   
Fx inflow Rs m18635,384 0.5%   
Fx outflow Rs m1,82110,399 17.5%   
Net fx Rs m-1,63524,985 -6.5%   
CASH FLOW
From Operations Rs m2,53111,493 22.0%  
From Investments Rs m-8,270-11,372 72.7%  
From Financial Activity Rs m-386-93 414.3%  
Net Cashflow Rs m-6,12528 -21,565.1%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.8 16.9%  
FIIs % 1.6 19.0 8.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.2 125.0%  
Shareholders   41,647 31,796 131.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 17, 2018 03:35 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - TORRENT PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS